What is Strand Diagnostics/Know Error?
Know Error develops a patented system that employs forensic principles and bar coding to ensure surgical biopsy samples are accurately matched to patients and free from contamination. Their solutions are designed for healthcare centers, medical practices, and pathology labs, enhancing patient safety and diagnostic accuracy in the biopsy process. The Know Error DNA test utilizes a buccal swab-to-biopsy tissue comparison to prevent cancer misdiagnosis and confirm correct patient attribution. By addressing specimen provenance complications, Know Error aims to mitigate the clinical and economic impacts associated with misidentified specimens, positioning itself as a critical player in medical diagnostics.
How much funding has Strand Diagnostics/Know Error raised?
Strand Diagnostics/Know Error has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2012): $30M with participation from NantWorks, LLC
Key Investors in Strand Diagnostics/Know Error
NantWorks, LLC
NantWorks is a research and development company specializing in advanced technology solutions, including machine vision and semiconductors, with a focus on innovative applications for the healthcare sector.
What's next for Strand Diagnostics/Know Error?
With a major strategic investment and a substantial total funding history, Know Error is poised for significant expansion and further development of its diagnostic integrity systems. This capital infusion is expected to accelerate the adoption of their technology across healthcare institutions, reinforcing patient safety protocols and improving the reliability of diagnostic outcomes. The company's focus on preventing misdiagnosis and ensuring specimen accuracy aligns with the growing demand for robust healthcare IT solutions, suggesting a trajectory towards broader market penetration and potential leadership in the specialized field of biopsy sample verification.
See full Strand Diagnostics/Know Error company page
